[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359852-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359852-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","helical-tomotherapy-in-local-advanced-breast-cancer-following-mastectomy-long-term-results-and-late-toxicity-analysis","Helical Tomotherapy in Local Advanced Breast Cancer Following Mastectomy - Long-term Results and Late Toxicity Analysis","","Adjuvant radiotherapy is a central component of treatment for locally advanced breast cancer after mastectomy. This single-center retrospective analysis evaluates female patients (n=38) treated with helical tomotherapy (hT) using a cumulative involved chest wall dose of 50.4 Gy, with lymphatic drainage pathways and a scar boost up to 60.4 Gy. Long-term local control, metastasis and survival outcomes, and retrospective toxicity including secondary malignancies were assessed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/helical-tomotherapy-in-local-advanced-breast-cancer-following-mastectomy-long-term-results-and-late-toxicity-analysis/359852/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/helical-tomotherapy-in-local-advanced-breast-cancer-following-mastectomy-long-term-results-and-late-toxicity-analysis/359852.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study investigating about helical tomotherapy after mastectomy?","Question",{"text":63,"@type":64},"The study investigates long-term clinical outcomes of helical tomotherapy following mastectomy for locally advanced or lymph node-positive breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were radiation doses delivered in the helical tomotherapy approach?",{"text":68,"@type":64},"Postmastectomy radiation therapy to the involved chest wall used a cumulative dose of 50.4 Gy, with lymphatic drainage pathways when tumor cells were present and a scar boost irradiation up to a cumulative dose of 60.4 Gy.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main long-term outcome and toxicity findings?",{"text":72,"@type":64},"Mean follow-up was 80 months, with 5- and 8-year local control rates of 97.2%, metastasis-free survival of 61.6% and 58%, and overall survival of 83.9% and 66%. Acute erythema was recorded, grade 3 events were not observed as serious adverse events above grade 3, and only one secondary malignancy occurred 24 months after PMRT.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359852,1790513165,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","doi: 10.21873/invivo.14305  \nHelical Tomotherapy in Local Advanced Breast Cancer Following Mastectomy: Long-term Results and Late Toxicity Analysis  \nLUIS-PHILIPP RAETHER1,2, MICHAELSCHEMPP2, RUDOLF KLEPPER2, HENRIK HAUSWALD3,4, SEBASTIAN HOEFEL2,5, PETER E. HUBER4,6, JUERGEN DEBUS4,6 and FELIX ZWICKER2,4,6  \n1 Heidelberg University School of Medicine, Heidelberg, Germany;  \n2Clinic and Practice of Radiation Oncology/Practice of Radiology, Konstanz, Germany;  \n3 RNS Gemeinschaftspraxis, Wiesbaden, Germany;  \n4Clinical Cooperation Unit Molecular Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany;  \n5 Department of Chemistry and Konstanz Research School Chemical Biology, University of Konstanz, Konstanz, Germany;  \n6 Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany  \nAbstract  \nBackground/Aim: Adjuvant radiotherapy is a key part of the overall treatment plan for local advanced breast cancer. In this study, we investigated the long-term clinical outcomes of helical tomotherapy (hT) following mastectomy. Patients and Methods: Female patients (n=38) with locally advanced or lymph node-positive breast cancer who had undergone mastectomy, sentinel-node biopsy, and/or axillary lymph node dissection were included in this singlecenter analysis. Postmastectomy radiation therapy (PMRT) to involved chest wall was applied by using hT with cumulative dose of 50.4 Gy. Lymphatic drainage pathways were included when they contained tumor cells. Generally, additional mastectomy scar boost irradiation (10 Gy) was applied up to a cumulative dose of 60.4 Gy. Local control (LC), metastasis, survival, toxicity, and secondary malignancy rates were analyzed retrospectively.  \nResults: The mean follow-up duration was 80 months. LC rates at 5 and 8 years were 97.2%, while metastasis-free survival (MFS) rates were 61.6% and 58%, respectively. Overall survival (OS) rates at 5 and 8 years were 83.9% and 66%, respectively. The occurrence of acute erythema was recorded in 60.5%(grades 1-2) and 23.7%(grade 3) of patients. 18.4% of treated patients developed grade 1 ipsilateral arm lymphedema and 5.3% grade 2. Serious adverse events, higher than grade 3, were not seen. Only one patient showed secondary malignancy 24 months after PMRT.  \ncontinued  \n✉ Felix Zwicker, MD, German Cancer Research Centre (DKFZ) E055, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.  \nTel: +49 (0)622142 2616, e-mail: [f.zwicker@dkfz.de](f.zwicker@dkfz.de)  \nReceived February 11, 2026 | Revised March 12, 2026 | Accepted March 16, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nConclusion: Excellent long-term results and low toxicity rates can be achieved in patients with locally advanced breast cancer by applying PMRT using hT. We are the first to report on the very low late toxicity rates and incidence of secondary malignancies. Our data suggests that broader clinical implementation of hT could benefit these patients.  \nKeywords: Breast cancer, helical tomotherapy, mastectomy, adjuvant radiotherapy, postmastectomy radiation therapy, scar boost radiation.  \nIntroduction  \nBreast cancer is the most frequently diagnosed malignancy in women worldwide and remains a principal cause of cancer-related mortality (1). Therefore, this disease is still the subject of intensive research (2-5). Mastectomy persists as an essential treatment modality, particularly for locally advanced or multifocal tumors where breast conserving surgery is not possible. Patients with triple-negative and luminal B differentiated breast cancers have a poorer prognosis (6, 7). Among the curative multi-modal treatment approaches available for loco-regional advanced breast cancer, post-mastect","cbCaij789ZmvHhzx","https://ap.wps.com/l/cbCaij789ZmvHhzx","pdf",1669239,18,"English","# Background/Aim\n# Patients and Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the study investigating about helical tomotherapy after mastectomy?\",\"answer\":\"The study investigates long-term clinical outcomes of helical tomotherapy following mastectomy for locally advanced or lymph node-positive breast cancer.\"},{\"question\":\"How were radiation doses delivered in the helical tomotherapy approach?\",\"answer\":\"Postmastectomy radiation therapy to the involved chest wall used a cumulative dose of 50.4 Gy, with lymphatic drainage pathways when tumor cells were present and a scar boost irradiation up to a cumulative dose of 60.4 Gy.\"},{\"question\":\"What were the main long-term outcome and toxicity findings?\",\"answer\":\"Mean follow-up was 80 months, with 5- and 8-year local control rates of 97.2%, metastasis-free survival of 61.6% and 58%, and overall survival of 83.9% and 66%. Acute erythema was recorded, grade 3 events were not observed as serious adverse events above grade 3, and only one secondary malignancy occurred 24 months after PMRT.\"}]","Helical Tomotherapy in Local Advanced Breast Cancer Following Mastectomy - Long-term Results and Late Toxicity Analysis | PDF",1790138018,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16af72331098a7dcdd50f0a24ad36c13.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/740cb26543c713532589acd0b5fa834f.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93c43463594b6c0272ff00d11821e156.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cbd381d87b77ae8613f902290ced723.webp",980,1306]